

April 30, 2013

Harvard Bioscience to Participate in Press Conference Today to Discuss Landmark Surgery

Team Involved in the Surgery to Address Media Only Today at 11:00 a.m. ET

HOLLISTON, Mass., April 30, 2013 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq:HBIO), a global developer, manufacturer and marketer of a broad range of tools to advance life science research and regenerative medicine, will participate in a press conference today at 11:00 a.m. ET regarding its involvement in a landmark surgery that involved materials manufactured by Harvard Apparatus Regenerative Technology, the wholly owned regenerative medicine technology subsidiary of Harvard Bioscience. David Green, Harvard Bioscience's President, will be present and available for questions from the media.

Those interested in listening to the press conference may dial-in via phone at (309) 624-1000 or (855) 749-6781. Conference ID: 475283.

A subsequent press release will be issued later this morning that will disclose greater detail.

About Harvard Bioscience

Harvard Bioscience, or HBIO, is a global developer, manufacturer and marketer of a broad range of specialized products, primarily apparatus and scientific instruments, used to advance life science research and regenerative medicine. HBIO sells its products to thousands of researchers in over 100 countries primarily through its 850 page catalog (and various other specialty catalogs), its website, through distributors, including GE Healthcare, Thermo Fisher Scientific and VWR, and via our field sales organization. HBIO has sales and manufacturing operations in the United States, the United Kingdom, Germany, Sweden and Spain with additional facilities in France and Canada. For more information, please visit www.harvardbioscience.com.

The Harvard Bioscience, Inc. logo is available at <http://www.globenewswire.com/newsroom/prs/?pkgid=6426>

About Harvard Apparatus Regenerative Technology, Inc.

Harvard Apparatus Regenerative Technology, Inc., a wholly owned subsidiary of Harvard Bioscience, develops and manufactures devices for use within the emerging field of regenerative medicine. These devices include bioreactors and synthetic scaffolds for growing tissue and organs outside the body; and injectors for stem cell therapy.

Registration Statement of Harvard Apparatus Regenerative Technology, Inc.

A registration statement including a prospectus relating to the common stock of Harvard Apparatus Regenerative Technology, Inc. has been filed with the SEC but has not yet become effective. These securities may not be sold nor may offers to buy these securities be accepted before the time the registration statement becomes effective. This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Forward-Looking Statements

Some of the statements in this press release are "forward-looking" and are made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995. These "forward-looking" statements include statements relating to, among other things, activities of Harvard Bioscience and the postponed IPO and other activities of Harvard Apparatus Regenerative Technology. These statements involve risks and uncertainties, including among other things, market conditions that may cause results to differ materially from the statements set forth in this press release. The forward-looking statements in this press release speak only as of the date of this press release. Harvard Bioscience expressly disclaims any obligation or undertaking to release publicly any updates or revisions to such statements to reflect any change in its expectations with regard thereto or any changes in the events, conditions or circumstances on which any such statement is based.

CONTACT: David Green, President

dgreen@harvardbioscience.com

Tom McNaughton, CFO

tmcnaughton@harvardbioscience.com

Chane Graziano, CEO

cgraziano@harvardbioscience.com

Tel: 508 893-8999

Fax: 508 892-6135

Dian Griesel Inc.

Investors:

Cheryl Schneider

212-825-3210

cschneider@dgicomm.com

Media:

Laura Radocaj

212-825-3210

lradocaj@dgicomm.com